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Respiratory failure, driven by airways mucus obstruction, chronic inflammation and
bacterial infections, is the main cause of mortality and morbidity in people with
cystic fibrosis (CF) due to defects in the Cl− and HCO−3 transport activity of the CF
Transmembrane conductance Regulator (CFTR). Most recent pre-clinical and clinical
studies have focused on restoring CFTR function by enhancing its trafficking or transport
activity and show promising results. However, there are a significant number of patients
that will not benefit from these CFTR-targeted therapies and it is therefore important
to identify new non-CFTR targets that will restore lung function, by-passing CFTR
dysfunction. The H+/K+-ATPase, ATP12A, has recently been identified as a potential
novel target for CF therapies, since its acute inhibition by ouabain was shown to help
restore mucus viscosity, mucociliary transport, and antimicrobial activity using in vitro
CF airway models, and this effect was linked to an increase in the pH of the airway
surface liquid (ASL). Here, we have evaluated the potential therapeutic use of ouabain
by investigating the effect of chronically treating fully differentiated CF primary human
airway epithelial cells (hAECs) with ouabain, under thin film conditions, resembling the
in vivo situation. Our results show that although chronic treatment increased ASL pH,
this correlated with a deleterious effect on epithelial integrity as assessed by LDH
release, transepithelial electrical resistance, fluorescein flux, and ion transport. Since
ATP12A shares approximately 65% identity with the gastric H+/K+-ATPase (ATP4A),
we investigated the potential of using clinically approved ATP4A proton pump inhibitors
(PPIs) for their ability to restore ASL pH in CF hAECs. We show that, despite not
expressing ATP4A transcripts, acute exposure to the PPI esomeprezole, produced
changes in intracellular pH that were consistent with the inhibition of H+ secretion,
but this response was independent of ATP12A. More importantly, chronic exposure
of CF hAECs to esomeprazole alkalinized the ASL without disrupting the epithelial
barrier integrity, but this increase in ASL pH was consistent with a decrease in mRNA
expression of ATP12A. We conclude that PPIs may offer a new approach to restore ASL
pH in CF airways, which is independent of CFTR.
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INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive
genetic disease in Caucasian populations and affects more than
70,000 people worldwide (Kelly, 2017). It is due to mutations
in the Cystic Fibrosis Transmembrane conductance Regulator
(CFTR) gene encoding an anion channel, transporting primarily
Cl− and HCO−3 in epithelial tissues (Saint-Criq and Gray, 2017).
CF is characterized by severe lung pathophysiology where thick,
sticky, mucus provides a favorable environment for bacterial
colonization, which, together with the initial CFTR defect, are the
cause of a chronic inflammation that leads ultimately to organ
failure. The CFTR channel is an essential regulator of the airway
surface liquid (ASL) composition (Namkung et al., 2009; Van
Goor et al., 2009; Luan et al., 2017). This thin fluid layer lines
the airway epithelium, and contributes to the efficient physical
and chemical barrier mechanism against inhaled particles and
pathogens by regulating ciliary beating, mucociliary transport,
and antimicrobial activity. Through its Cl− and HCO−3 transport
activities, CFTR controls water movement across the epithelium
and thus ASL hydration as well as its pH, respectively. However,
the absolute value of the ASL pH in people with CF is still
controversial as the measurement of this parameter in such a thin
layer of fluid has proven very difficult. Although previous reports
have shown an acidic ASL pH in human and animal models of
CF airways (Coakley et al., 2003; Song et al., 2006; Pezzulo et al.,
2012; Birket et al., 2018), the most recently published in vivo
study reported no difference in ASL pH between children with or
without CF (Schultz et al., 2017). Nevertheless, multiple studies
have shown the importance of pH homeostasis in the ability of
the airways to maintain ASL hydration (Garland et al., 2013),
fight infections (Berkebile and McCray, 2014; Tang et al., 2016)
and remove trapped microorganisms from the lungs (Quinton,
2008; Tang et al., 2016). Therefore increasing HCO−3 or inhibiting
H+ secretion could be a suitable therapeutic strategy for lung
disease in CF. To date, most pre-clinical research has focused
on restoring CFTR function using CFTR-directed therapeutics.
Gating mutants such as G551D (and others) respond very well
to the CFTR potentiator, Ivacaftor, as well as a number of
residual function mutations (De Boeck and Amaral, 2016) and
next generation correctors appear able to restore some function
to the most common CF-causing mutation (F508del) (Taylor-
Cousar et al., 2017; Vertex, 2017). However, around 15% of
people with CF lack the F508del mutation in both alleles and a
certain percentage of these individuals who express F508del in at
least one allele, experienced limited benefit from next generation
CFTR modulators (NCT01225211; Boyle et al., 2014; Rowe
et al., 2017). Therefore, there is an unmet need for alternative,
mutation-independent, therapies that restore lung function in all
people with CF. Accordingly, targeting non-CFTR H+ or HCO−3
channels or transporters, is a promising therapeutic strategy.
A recent study in mouse, pig and human airways has shown
the essential role of the non-gastric H+/K+-ATPase, ATP12A, in
ASL pH regulation in CF (Shah et al., 2016). Here the absence
of expression of this ATPase in mice was linked to the mild
pulmonary phenotype in the CF animals. On the other hand,
acute (2 h) inhibition of this pump in pig and human airway
cultures by a high concentration of apical ouabain, increased ASL
pH and restored bacterial killing and mucus viscosity. This study
showed for the first time the potential therapeutic use of ouabain
in CF airways by targeting ASL pH homeostasis. However, to
our knowledge no one has investigated the long-term effects
of apical exposure to this widely used cardiac glycoside, that
also inhibits the basolateral Na+/K+-ATPase, a key transporter
essential for transepithelial ion and fluid transport, on airway
epithelial cells. Moreover, as ATP12A belongs to the family of
hydrogen-potassium ATPases (Crambert et al., 2002) and shares
significant sequence and functional homology with the gastric
form of the H+/K+-ATPase (ATP4A), for which there are a
number of well-characterized proton pump inhibitors (PPIs)
(Iwakiri et al., 2016) in use clinically, it was of interest to test the
efficiency of these PPIs on airway cell function.
Therefore, in this study we tested the effects of long-term
apical ouabain treatment on CF primary human airway epithelial
cells (hAECs) ASL pH and epithelial integrity and compared this
to the response to one of the commonly used PPIs, esomeprazole.
We show for the first time that although apical treatment with
ouabain increased ASL pH in a dose-dependent manner, this
was positively correlated with an increase in cytotoxicity and
disruption of epithelial barrier function. On the other hand, even
though the gastric H+/K+-ATPase was not expressed in airway
epithelial cells, exposure to esomeprazole acidified the cytosol
and increased ASL pH of primary CF hAECs. We show that
esomeprazole had a dual mechanism of action: acutely, it induced
intracellular acidification in an ATP12A-independent manner
but, chronic exposure, which importantly did not have any
deleterious effect on epithelial integrity, was linked to decreased
ATP12A mRNA levels. These results open up the possibility of
repurposing PPIs as a new therapeutic approach for treating CF
lung disease.
MATERIALS AND METHODS
Chemicals
Ouabain (O3125), esomeprazole (E7906), N-Acetyl-L-cysteine
(A7250), amiloride (A7410), fluorescein (F6377), mitomycin
C (M0503), and UTP (U6750) were purchased from Sigma-
Aldrich. Forskolin (1099), Y-27632 (1254), and CFTRInh172
(3430) were purchased from Tocris (RnD). The fluorescent
dyes, Alexa FluorTM 488- Dextran (D22910); pHrodoTM Red
Dextran (P10361) and BCECF, AM (2′,7′-Bis-(2-Carboxyethyl)-
5-(and-6)-Carboxyfluorescein, Acetoxymethyl Ester) (B1150)
were purchased from ThermoFisher Scientific.
Solutions
See Table 1.
Cell Culture
Primary non-CF (n = 3 donors) and CF (n = 3 donors,
all F580del/F508del) hAECs were a kind gift from Dr. Scott
H. Randell (Marsico Lung Institute, The University of North
Carolina at Chapel Hill, United States). The cells were
obtained under protocol #03-1396 approved by the University
Frontiers in Pharmacology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 1462
fphar-09-01462 December 8, 2018 Time: 10:14 # 3
Delpiano et al. Esomeprazole Regulates CF ASL pH
TABLE 1 | Composition of the solutions used in this study. Concentrations are given in mM.
HCO−3
KRB
low Cl− NaCl
HEPES
High K+
HEPES/Nigericin
K+-free
solution (0K+)
ASL pH standard
curve solution
ASL pH standard
curve solution
ASL pH standard
curve solution
pH at 37◦C 7.4 7.4 7.4 6/6.9/7.5 7.4 5.5-6-6.5 7-7.5 8
NaHCO3 25 25 25
NaCl 115 130 5 120 86 86 86
KCl 5 5 5 130 5 5 5
CaCl2 1 1.2 1 1 1 1.2 1.2 1.2
MgCl2 1 1.2 1 1 1 1.2 1.2 1.2
D-Glucose 5 5 5 5 5
Na-gluconate 115
K2SO4
Ca-gluconate 2.8
Mg-gluconate
NaHEPES 10 10 100
MES 100
Tris 100
of North Carolina at Chapel Hill Biomedical Institutional
Review Board. Primary cells from three different CF donors
(all F580del/F508del) were obtained via the CFFT Biorepository.
They were expanded using the conditionally reprogrammed cell
(CRC) culture method as previously described (Suprynowicz
et al., 2012). Briefly, cells were seeded on 3T3J2 fibroblasts
inactivated with mitomycin C (4 µg/ml, 2 h, 37◦C) and grown
in medium containing the ROCK inhibitor Y-27632 (10 µM)
until they reached 80% confluence. Cells then underwent double
trypsinization to remove the fibroblasts first and then detach the
hAECs from the P150 dish. At that stage, cells were counted
and could be frozen down. Cryopreserved cells were seeded
onto semi-permeable supports (6.5 or 12 mm) in bilateral
differentiating medium (ALI medium) as previously described
(Randell et al., 2011). The apical medium was removed after 3–
4 days and cells then allowed to differentiate under air-liquid
interface (ALI) conditions. Ciliogenesis started approximately
12–15 days after seeding and cells were used for experiments
between days 25 and 35 after seeding.
Knock-Down of ATP12A Using
CRISPR-Cas9
Guide RNA (gRNA) sequences targeting upstream (5′-
GGCCGGAGGGAGTCGGACAG-3′) and downstream
(5′-TCCCTCAGACTGAATGTCTG-3′) of ATP12A exon 2
were designed using the Optimized CRISPR Design Tool1. Single
stranded DNA oligonucleotides (IDT) containing the gRNA
sequence in addition to the BbsI restriction enzyme sequences
were annealed (95 to 25◦C, 1-6◦C/min). The double stranded
oligonucleotides were then ligated into the CRISPR-Cas9 vector,
PX462, following BbsI linearization, using T4 ligase (Invitrogen)
overnight at 16◦C. To validate the sequences, cells from the
human chondrocyte cell line Tc28a2 were nucleofected [106 cells,
5 µg of plasmid DNA using the manufacturer recommended
1crispr.mit.edu/
Cell Line 4D-Nucleofector X Kit in combination with the 4D-
Nucleofector System (Lonza)] and selected with puromycin after
24 h. Following expansion, nucleic acids were extracted using
the EZNA DNA/RNA Isolation kit (Omega Bio-Tek) according
to the manufacturer’s protocol. Deletion of the target region was
confirmed using end-point PCR (Supplementary Figure 6D).
Following validation in the Tc28a2 cells, primary CF hAECs
were transfected using an adapted version of a previously
published protocol (Ramachandran et al., 2013). Briefly, DNA
(3 µg) was incubated for 3 min in ALI medium without
antibiotics, FuGENE HD Transfection Reagent was then added
(3:1 ratio) and further incubated for 15 min at room temperature
on the collagen-coated semi permeable supports. Freshly thawed
cells were counted and seeded onto the semi-permeable support
in antibiotics-free ALI medium. After 5 h incubation, medium
was replaced and cells were grown as previously described in
antibiotics containing ALI medium from day 3. After pHi or
ASL pH experiments, RNA was extracted as described below and
ATP12A mRNA was quantified by RT-qPCR.
ASL pH Measurements
Cells grown on 6.5 mm transwells were washed apically with
120 µl glucose-free HCO−3 -containing Krebs solution (HCO
−
3
KRB, Table 1) for 15 min at 37◦C, 5% CO2. The ASL was
stained using 3 µl of a mixture of dextran-coupled pH-sensitive
pHrodo Red (0.5 mg/ml, λex: 565 nm, λem: 585 nm) and
Alexa Fluor R© 488 (0.5 mg/ml, λex: 495 nm, λem: 519 nm)
diluted in glucose-free HCO−3 KRB, overnight at 37◦C, 5% CO2.
Alexa Fluor R© 488 was used as a loading control as pHrodo is
not a ratiometric dye. The next day, fluorescence was recorded
using a temperature and CO2-controlled plate reader (TECAN
SPARK 10M). After subtracting background values from pHrodo
and Alexa Fluor R© 488, ratios were generated for each time
point and pH was calculated from a standard curve where pH
was clamped using highly buffered solutions between 5.5 and
8 (see Table 1 for composition). To prevent inter-experiment
variability, the standard curve calibration was performed on each
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independent experiment. For ASL pH experiments involving
apical exposure to chemicals, cells were treated overnight with
the compounds, which were added with the fluorescent dyes at
0.1X final concentration. The final concentrations of the drugs
added was calculated assuming a theoretical final ASL volume of
0.3 µl (10 µm × pi × 3.25 mm2), after absorption of the excess
fluid by the epithelium. ASL pH measurements were performed
in duplicate.
Transepithelial Electrical Resistance,
Fluorescein Flux, and Short−Circuit
Current Measurements in Ussing
Chamber
Cells grown on 6.5 mm inserts were mounted into the EasyMount
Ussing Chamber Systems (VCC MC8 Physiologic Instrument)
and bathed in basolateral HCO−3 KRB and apical low Cl−
(Table 1) continuously gassed and stirred with 5% (v/v)
CO2/95% (v/v) O2 and maintained at 37◦C. Monolayers were
voltage-clamped to 0 mV and monitored for changes in short-
circuit current (1Isc) using Ag/AgCl reference electrodes. The
transepithelial short-circuit current (Isc) and the TransEpithelial
Electrical Resistance (TEER) were recorded using Ag–AgCl
electrodes in 3 M KCl agar bridges, as previously described
(Saint-Criq et al., 2013), and the Acquire & Analyze software
(Physiologic Instruments) used to perform the analysis.
Fluorescein Flux
A 100 µl sample (blank) was taken from the apical bath
5 min after mounting the monolayers and 100 µl of fluorescein
(20 µg ml−1 final concentration) was then added to the
basolateral bath. Apical samples (100 µl) were collected every
5 min for 45 min and replaced by the same volume of fresh
warmed low Cl− solution. Collected samples were loaded onto a
96 well plate and fluorescence was measured using a plate reader
(λex: 460 nm; λem: 515 nm). Data is presented as the slope
of fluorescein appearance in the apical bath and was obtained
after plotting (sample-blank) vs. time and performing a linear
regression. The addition of the fluorescein solution, as well as the
collection and replacement of apical samples, did not have any
effect on the TEER or Isc.
Short−Circuit Current Measurements
After the last fluorescein flux samples were collected, cells
were left to equilibrate for a further 10 min and ion transport
agonists and inhibitors were added following this sequence:
amiloride (10 µM, apical), Forskolin (Fsk, 10 µM, bilateral),
CFTRinh172 (172, 20 µM, apical) and UTP (100 µM, apical).
Results were normalized to an area of 1 cm2 and expressed as Isc
(µAmp.cm−2).
Intracellular pH Measurements
Primary airway epithelial cells were grown on 12 mm Transwell
inserts and loaded with the pH-sensitive, fluorescent dye BCECF-
AM (10 µM) for 1 h in a Na-HEPES buffered solution (see
Table 1) at 37◦C. Cells were mounted on to the stage of a
Nikon fluor inverted microscope and perfused with a modified
Krebs solution gassed with 5% (v/v) CO2/95% (v/v) O2. Solutions
were perfused across the apical and basolateral membranes at
37◦C at a speed of 3 and 6 ml min−1, respectively. Intracellular
pH (pHi) was measured using a Life Sciences Microfluorimeter
System in which cells were alternately excited at 490 and 440 nm
wavelengths every 1.024 s with emitted light collected at 510 nm.
The ratio of 490 to 440 nm emission was recorded using
PhoCal 1.6 b software and calibrated to pHi using the high
K+/nigericin technique (Turner et al., 2016) in which cells were
exposed to high K+ solutions containing 10 µM nigericin, set
to a desired pH, ranging from 6 to 7.5. For analysis of pHi
measurements, 1pHi was determined by calculating the mean
pHi over 60 s resulting from treatment. The initial rate of
pHi change (1pHi/1t) was determined by performing a linear
regression over a period of at least 40 s.
RNA Extraction and Real-Time
Quantitative PCR Analysis
RNA isolation from cells was performed using PureLink R© RNA
Mini Kit (12183018A, Ambion, Life Technologies), following
the manufacturer’s instructions. Briefly, lysates were mixed
with 70% ethanol and loaded onto a silica-membrane column.
Columns were washed with different buffers and total RNA
was eluted in DNAse and RNAse-free water and stored at
−80◦C until use. DNase treatment was performed on 300 ng
RNA prior to Reverse Transcription Polymerase Chain Reaction
(RT-PCR) using RNAse-free DNAse I (04716728001, Roche) at
37◦C for 10 min. Reaction was then stopped by increasing the
temperature to 70◦C for 10 min. Complementary DNA (cDNA)
was synthesized from total RNA (300 ng) using M-MLV Reverse
Transcriptase (Promega) as per supplier’s protocol (1 h at 37◦C
followed by 10 min at 70◦C).
Real-time quantitative PCR (qPCR) was performed in a total
volume of 15µl using 2× LightCycler R© 480 SYBR Green I Master
(Roche, 04707516001), 1.5 µl of cDNA, 2 µM forward primer
and 2 µM reverse primer in a 96-well plate. Primer sequences are
shown in Table 2. The expression of GAPDH was used as internal
control. PCR was run with the standard program: 95◦C 10 min,
40 times of cycling 95◦C 15 s and 60◦C 1 min in a 96-well plate.
Results are shown as Threshold Cycle (Ct) or Relative quantity of
mRNA copies to the determined control condition. A Ct value of
40 was applied for samples in which no messenger was detected.
TABLE 2 | qRT-PCR primers for mRNA quantification.
Target Oligo sequence PCR product length
ATP12A 5′-GGGGCACACTTGTTCATCTTCTGA-3′ 128
5′-GCAAAACATCAGTGAGCATCCTG-3′
ATP4B 5′-GGCCTTCTACGTGGTGATGAC-3′ 136
5′-CCCGTAAACATCCGGCCTTA-3′
ATP4A 5′-AAGATCTGCAGGACAGCTACGG-3′ 200
5′-CTGGAACACGATGGCGATCA-3′
GAPDH 5′-TGC ACC ACC AAC TGC TTA GC-3′ 87
5′-GGC ATG GAC TGT GGT CAT GAG-3′
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Cell Cytotoxicity Measurement
Cell cytotoxicity was measured by quantification of secreted
lactate dehydrogenase (LDH), after overnight exposure to vehicle
or drugs. This was calculated after measurement of the apical
+ basolateral LDH release (LDHsec) and expressed as a ratio
to the cell lysates LDH (PBS/Triton X-100 0.8%; LDHlysate).
Samples were diluted in PBS/Triton X-100 0.8%, loaded onto
a 96 well plate (Costar) and incubated with the assay reagent
for 30 min at room temperature in the dark. After addition
of the stop solution, absorbance was measured at 490 nm (kit
CytoTox96 R© Non-Radioactive Cytotoxicity Assay kit, Promega)
in a TECAN Infinite M200pro plate reader. Data were analyzed
and cytotoxicity was calculated as follows:
% cytotoxicity =
(
OD LDHsec
OD LDHsec +OD LDHlysate
)
× 100
Statistical Analysis
All analyses were performed using GraphPad Prism7. Where
applicable, results are shown as mean ± SEM. Dose responses
were analyzed by non-linear regression on a log scale (log[drug]
vs. response) and IC50 were compared by the extra sum-of-
squares F-test. For some data, correlations were tested and
Pearson correlation coefficient given in the text. Parametric
and non-parametric data distributions were assessed with the
D’Agostino & Pearson normality test. Multiple group and two-
group comparisons were performed using appropriate statistical
tests for specific data sets (see details in individual figure legends).
RESULTS
The Activity of ATP12A Is Not Different
Between CF and Non-CF hAECs
As ATP12A was suggested to be a key regulator of ASL pH
(Shah et al., 2016), we investigated its expression and activity in
fully differentiated primary cultures of CF and non-CF primary
hAECs. Quantitative (q)PCR showed that the level of mRNA
expression of ATP12A was not different between primary CF
and non-CF hAECs (Supplementary Figure 1). Because ATP12A
has previously been shown to be constitutively active in airway
cells (Coakley et al., 2003; Shah et al., 2016; Lennox et al., 2018),
inhibition of this pump, by acute exposure to ouabain, would
be predicted to cause an intracellular acidification. Therefore, to
functionally assess ATP12A activity, we measured the acute effect
of increasing concentrations of apical ouabain on intracellular pH
(pHi) in primary CF and non-CF hAECs, loaded with the pH-
sensitive dye BCECF-AM (see section “Materials and Methods”).
Figures 1A,B shows that, as predicted, acute exposure to apical
ouabain lead to a dose-dependent, reversible, acidification in
both non-CF and CF cultures, respectively. Analysis of the dose-
response curves showed that although the maximal change in pHi
FIGURE 1 | Characterization of ATP12A activity in non-CF and CF primary hAECs. Non-CF and CF hAECS acidify in response to acute apical ouabain. Upper panels
show representative traces of pHi responses to acute increasing apical concentrations of ouabain in non-CF (A) and CF (B) hAECs. Change in pHi (C) and rate of
acidification (D) of non-CF (black circles, n ≥ 7, three donors) and CF (gray squares, n ≥ 5, five donors) hAECs in response to acute increasing concentrations of
apical ouabain. Results show no significant difference in change in pHi or rate of acidification between non-CF and CF hAECs (non-linear regression with comparison
of fits; change in pHi: p = 0.51; rate: p = 0.64).
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induced by 1 mM ouabain was somewhat lower in CF versus non-
CF cells, the IC50 calculated from the change in pHi (Figure 1C)
as well as from the rate of acidification (Figure 1D) induced
by ouabain were not significantly different (IC50: 1pHi non-
CF = 165.2 µM, n ≥ 7; CF = 102.3 µM, n ≥ 5, p = 0.506; rates
of acidification non-CF = 153.6 µM, n ≥ 7; CF = 217.4 µM,
n ≥ 5, p = 0.636). Our results, obtained from 12 independent
experiments (n = 7 non-CF/2 different donors and n = 5
CF/3 different donors), also showed that baseline pHi was not
significantly different between non-CF and CF hAECs. Due to
the potential beneficial effect of inhibiting H+ secretion in CF
epithelia, the rest of the study then focused on primary CF
hAECs.
Chronic Apical Ouabain Treatment
Alkalinized the ASL
In view of the fact that acute treatment using 100 µM ouabain
induced a significant intracellular acidification near to the IC50,
we then investigated the effect of treating CF cells overnight with
30 to 100 µM ouabain on ASL pH. After overnight incubation,
the cells were transferred to a CO2 and temperature-controlled
plate-reader and ASL pH was recorded every 5 min for 2 h
before addition of the cAMP agonist forskolin (Fsk) to the
basolateral compartment, and ASL pH recorded for a further
4 h. In the vehicle (DMSO)-treated cells, ASL pH was stable
over the entire course of the experiment (Figure 2A, black line)
whereas, ouabain-treated cell cultures showed a slow but steady
increase in ASL pH over time (Figure 2A, yellow, green, and blue
lines). Although increasing concentrations of ouabain appeared
to increase ASL pH in a dose-dependent manner it only reached
significance with the highest dose tested, 100µM (Figures 2A,B).
Surprisingly, and contrary to what other groups have reported
(Coakley et al., 2003; Shah et al., 2016) Fsk treatment did not
induce ASL acidification in CF cells. As ATP12A is inhibited by
ouabain or K+-free (0K+) solution, we confirmed our results
using a different technique. Here, we measured changes in pHi
in response to ouabain and 0K+ in the absence or presence of
FIGURE 2 | Ouabain increases ASL pH in primary CF hAECs in a dose-dependent manner. CF hAECs were treated overnight with increasing concentrations of
apical ouabain and ASL pH was then measured in real time (A) under resting conditions and after stimulation with forskolin (Fsk, basolateral, 10 µM) (n = 4 in
duplicate, three donors; data plotted as mean ± SEM). (B) Chronic ouabain increased resting ASL pH. Resting ASL pH was calculated as an average of five points
before addition of Fsk (Friedman’s test comparing ouabain-treated vs. vehicle-treated). (C) CF hAECs treated with ouabain show a slow and continuous increase in
ASL pH but do not respond to Fsk. The rate of increase in pH was calculated before and after addition of basolateral Fsk and compared using a two-way repeated
measures (RM)-ANOVA with Tukey’s test.
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FIGURE 3 | Apical ouabain disrupts epithelial integrity of primary CF hAECs. (A) LDH release in response to increasing concentrations of apical ouabain in primary
CF hAECs (n = 4, three donors; Friedman’s test comparing ouabain-treated vs. vehicle-treated). (B) Effect of increasing concentrations of apical ouabain on
TransEpithelial Electrical Resistance (TEER) and Fluorescein Flux assessed in Ussing chambers in the presence of a basolateral to apical Cl− gradient (n = 4).
(C) Correlation between TEER and Fluorescein Flux (Spearman correlation test: p < 0.001). Effect of increasing concentrations of apical ouabain on resting
short-circuit current (Isc, D, n = 4), amiloride-sensitive Isc (1Isc(amil), E, n = 4) and UTP-induced Isc (1Isc(UTP), F, n = 4).
10 µM Fsk. Results showed that Fsk itself, (1) did not alter pHi
(Supplementary Figure 2A) and (2) did not change the extent or
rate of ouabain and 0K+-induced acidification (Supplementary
Figures 2A–C).
As ASL pH slowly increased after addition of Fsk, we
determined if ouabain induced changes in CF hAECs that would
have sensitized them to Fsk (thereby inducing an increase in ASL
pH via CFTR), by measuring the rates of alkalinization before and
after addition of Fsk. As shown in Figure 2C, the initial rates of
alkalinization increased significantly in ouabain treated samples
when compared to vehicle-treated cells, but these rates were
unchanged after Fsk treatment, suggesting that chronic apical
ouabain treatment induced changes that allowed for a slow and
gradual increase in ASL pH. We hypothesized that chronic apical
ouabain treatment was having a deleterious effect on CF hAECs
and therefore assessed the effect of these treatments on epithelial
integrity.
Chronic Apical Ouabain Treatment
Disrupts Epithelial Integrity by Inhibiting
the Basolateral Na+/K+-ATPase
We first assessed the potential cytotoxic effect of the same
concentrations of ouabain used in the ASL pH experiment by
measuring LDH release after overnight exposure to the drug.
To do this, the apical surface of CF hAECs was washed with
50 µl of HCO−3 KRB for 30 min (37◦C, 5% CO2) and LDH
was measured in the apical washes as well as the basolateral
media. Figure 3A shows that 70 and 100 µM ouabain induced
a significant increase in LDH release. Even though the percentage
released remained under 10%, this increase in LDH release
was positively correlated with the increase in ASL pH (Pearson
r = 0.5278; p = 0.036). To confirm the deleterious effect of
chronic apical ouabain treatment on epithelial integrity, we
measured TEER and fluorescein flux across the epithelia as
well as the activity of the main ion channels expressed in
primary CF hAECs. Increasing concentrations of the ATP12A
inhibitor significantly decreased TEER and increased fluorescein
flux across the epithelia (Figure 3B). These two parameters were
inversely correlated as shown in Figure 3C (Pearson R =−0.809,
p< 0.001). Resting short circuit current increased with increasing
concentrations of ouabain (Figure 3D), whereas amiloride-
sensitive and UTP-induced currents were inhibited in a dose
dependent manner (Figures 3E,F, respectively). Fsk-induced
and CFTRinh172-sensitive Isc were minimal and remained
unchanged after treatment with increasing concentrations of
apical ouabain (data not shown).
To investigate if the deleterious effects of apical ouabain
treatment were due to an inhibition of the basolateral Na+/K+-
ATPase, cells were treated overnight with either 70 µM apical
ouabain or the equivalent basolateral concentration (30 nM),
assuming complete equilibration of the inhibitor from the apical
to the basolateral compartment (70 µM × 0.3 µl/700 µl).
As shown in Figure 4, treatment of CF hAECs with 30 nM
basolateral ouabain induced a decrease in TEER (Figure 4A),
an increase in fluorescein flux (Figure 4B) and resting Isc
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FIGURE 4 | Ouabain (Ouab)-induced epithelial disruption is mimicked by
inhibition of the basolateral Na+/K+-ATPase in primary CF hAECs. The effect
of 50 µM apical ouabain was compared to 30 nM basolateral ouabain on
TEER (A), fluorescein flux (B), resting Isc (C), 1Isc(amil) (D), and 1Isc(UTP) (E)
(all, n = 7, five donors, Friedman’s test comparing all conditions).
(Figure 4C) as well as an inhibition of amiloride-sensitive
(Figure 4D) and UTP-induced (Figure 4E) changes in Isc, that
were not significantly different from the changes induced by the
overnight apical treatment with 70 µM ouabain. Taken together,
these results show that the potential use of ouabain to target
ASL pH in CF is very likely to be deleterious and cytotoxic to
airway epithelial cells. To further investigate this, CF hAECs were
treated basolaterally with conditioned medium derived from the
basolateral compartment from cells treated apically with 30 µM
ouabain (for 24 h). This revealed that conditioned medium did
not fully reproduce the effects seen with apical exposure alone,
which suggests that either ouabain is metabolized during the
48 h incubation or that the cytotoxic effect of ouabain cannot
be solely explained by the inhibition of the serosal Na+/K+-
ATPase (Supplementary Figures 3A–E). It was thus of interest
to identify molecules that could specifically target apical H+
secretion, without affecting the Na+/K+-ATPase, as a non-
cytotoxic strategy to increase ASL pH in CF airways.
Esomeprazole Affects Intracellular pH
and Raises ASL pH in CF hAECs
Using Blastn, we found that the mRNA of ATP12A, the
non-gastric H+/K+-ATPase, shares 70% identity with the
gastric H+/K+-ATPase, ATP4A mRNA, which translates to
around 65% identity in the protein products (Blastp). This
H+ pump is targeted in gastric ulcers and gastroesophageal
reflux diseases (GERDs) by antacids, and especially PPIs. We
therefore investigated the effect of the PPI, esomeprazole (Eso)
on pH homeostasis in CF hAECs. It has been previously
published that airway epithelial cells do not express the gastric
H+ pump and this was confirmed in our cells in which we
found an average Ct value of 37.50 ± 1.53 in CF hAECs
and 40 in non-CF hAECs (compared to averaged values of
21.61 ± 0.21 in CF cells and 22.03 ± 0.66 in non-CF cells
for ATP12A, Supplementary Figure 4). We then assessed the
effect of increasing concentrations of apical Eso on pHi and
showed that CF hAECs responded in a dose dependent manner
(Figures 5A,B). To elucidate whether Eso targeted H+ or HCO3−
transport, pHi experiments were performed in the absence
(Hepes) or presence of HCO−3 (HCO
−
3 KRB). Figures 5C,D show
that Eso, as well as ouabain, inhibited H+ secretion and that the
effect of both was enhanced in the absence of HCO−3 .
As ouabain caused detrimental effects on epithelial integrity,
we then evaluated the effect of chronic exposure of CF hAECs
to increasing concentrations of Eso on TEER, fluorescein flux
and ion channel activity. Concentrations of Eso, ranging from
10 to 300 µM, showed no effect on any of these parameters
(Figures 6A–C) supporting a non-toxic effect of Eso on CF
hAECs.
Considering its effect on pHi (Figure 5) we then investigated
the effect of Eso on ASL pH. Primary CF hAECs were treated
overnight with 50, 100, or 300 µM Eso and the next day ASL
pH was monitored for 2 h before FSK was added basolaterally.
Although increasing concentrations of Eso appeared to increase
ASL pH in a dose-dependent manner (Figure 7A) it only reached
significance with the highest dose tested, 300 µM, which raised
resting ASL pH by 0.10 ± 0.02 (p = 0.001, n = 8, paired t-test,
Figures 7A–C) but did not change the response to Fsk by CF
hAECs (Figure 7D). This result, taken together with the Ussing
chamber experiments in which Eso did not change either Fsk-or
UTP induced Isc (Figure 6C), suggests that Eso does not increase
ASL pH in CF hAECs via an increase in either mutant CFTR,
or calcium-mediated anion secretion, but rather, it works via
inhibiting proton secretion.
Chronic Esomeprazole-Induced
Alkalization of the ASL but Not Acute
Intracellular Acidification Is ATP12A
Dependent
We then investigated the molecular target of acute and chronic
exposure to Eso. Intracellular pH was monitored during exposure
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FIGURE 5 | Acute esomeprazole decreases intracellular pH in primary CF hAECs by inhibiting H+ secretion. (A) Representative trace of the effect of increasing
concentrations of acute esomeprazole on pHi. (B) Summary data of the esomeprazole dose response on pHi (n ≥ 7, three donors). (C) Representative trace of the
effect of 1 mM apical ouabain (Ouab) or 300 µM apical esomeprazole (Eso) in the absence (Hepes) or presence of HCO−3 (HCO
−
3 KRB). (D) Summary data of the
effect of 1 mM apical ouabain (Ouab) or 300 µM apical esomeprazole (Eso) in the absence (Hepes) or presence of HCO−3 (HCO
−
3 KRB) presented as mean ± SEM
(n = 3, two donors, two-way ANOVA with Sidak’s post-test).
to acute Eso, 0K+, or Eso + 0K+. Eso and 0K+ induced
intracellular acidification in a similar manner (Figure 8, p = 0.28,
n = 11, RM ANOVA). However, Eso and 0K+ induced a
further decrease in pHi when compared to either 0K+ alone
(Figure 8B, n = 13, p < 0.001, RM ANOVA) or to Eso alone
(Figure 8B, n = 13, p < 0.001, RM ANOVA) suggesting that
the acute effect of Eso on pHi is independent of ATP12A and
targets another H+ transporter. Similar results were found using
ouabain (1 mM) instead of 0K+ in the same type of experiment
(Supplementary Figure 5, ouabain vs. Eso+ouab p = 0.03; Eso
vs. Eso+ouab p < 0.001; n = 10, RM ANOVA). Furthermore,
using CF hAECs in which ATP12A expression was reduced
by CRISPR-Cas9 (Supplementary Figure S6C), we found that
0K+ and ouabain-induced acidification were reduced by 44 and
52%, respectively (Supplementary Figures 6A,B) whereas Eso-
induced acidification was only decreased by 9% (Supplementary
Figures 6A,B).
In contrast, we identified ATP12A as a potential target
of chronic Eso treatment in CF hAECs. Indeed, RT-qPCR
showed that 24 h treatment with 300 µM Eso decreased
significantly mRNA levels of ATP12A (Figure 9A, p = 0.049,
n = 7, paired t-test). We confirmed this result using the
CRISPR-Cas9 method to knock down ATP12A expression.
Results showed that in cells where ATP12A levels were reduced
(Figure 9B, −17.1 ± 4.4%, p = 0.02, n = 6, paired t-test),
ASL pH increased (Figure 9C, p = 0.003, n = 6, two-way
ANOVA) and chronic Eso was not able to induce a further
increase in ASL pH (Figure 9C, p = 0.347, n = 6, two-way
ANOVA).
DISCUSSION
In the past few years, there has been increasing evidence that
extracellular ASL pH plays a major role in airway homeostasis
and defense against inhaled pathogens. Thus an acidic pH was
shown to reduce bacterial killing (Pezzulo et al., 2012), increase
ENaC activity and therefore ASL dehydration (Garland et al.,
2013; Tan et al., 2014) and increase mucus viscosity (Tang et al.,
2016). An acidic ASL in CF airways can be explained by a
defect in HCO−3 secretion (due to defective CFTR) and/or an
unregulated H+ secretion. Recently, it was shown that ATP12A,
was responsible for this unchecked H+ secretion in human
and pig CF airways and accounted for the increased mucus
viscosity and decreased bacterial killing ability (Shah et al., 2016)
promoting this pump as a valid target for CF airway disease.
We have shown that inhibition of the non-gastric H+/K+-
ATPase using ouabain concentrations close to the IC50
significantly increased ASL pH in CF hAECs. However, this
increase in ASL pH was not stable after overnight incubation with
the drug and a slow, but constant, alkalinization was observed
throughout the ASL pH measurement. This led us to suggest
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that upon chronic treatment with apical ouabain, the epithelia
were becoming leaky, allowing for the equilibration of the pH
between the basolateral (pH 7.4) and the apical compartments.
In kidney epithelia, it has been shown that chronic treatment
(3 days) with a low dose (1 µM) of ouabain induced the
disassembly of tight-junction proteins as well as cell adhesion
associated protein, leading to cell to cell and cell to surface
detachment (Larre et al., 2010; Rincon-Heredia et al., 2014).
Using a shorter treatment time frame, we showed that ouabain
disrupted CF airway epithelial integrity in a dose-dependent
manner, leading to an increase in LDH release, fluorescein
flux as well as a profound drop in transepithelial resistance. It
was also linked to a decrease in ENaC-mediated and calcium-
activated transepithelial transport, but not to an increase in CFTR
conductance (data not shown). The lack of effect of ouabain on
CFTR in CF cells is in contrast to the study from Zhang et al.
(2012) which showed that 24 h treatment with low concentrations
of cardiac glycosides, including ouabain, induced trafficking of
the F508del-CFTR to the cell surface in a cell line over-expressing
the mutated CFTR, mimicking the effect of low temperature
incubation (Zhang et al., 2012). This may be explained either
by the difference in concentrations used (0.1 vs. 10–300 µM) or
by a difference in the cell models. Indeed, the cell line used in
Zhang’s study overexpressed F508del-CFTR and it is therefore
more likely to detect small changes in CFTR trafficking and/or
transport activities and report effects that do not happen in a
non-overexpressing systems. Our experiments were performed
on primary CF hAECs from three different donors (all F508del
homozygous). Inter-donor variability was compensated for by
doing the statistical analysis using paired/repeated measure
settings and therefore we are confident about the lack of effect
of ouabain on mutant CFTR activity.
Surprisingly and contrary to what other groups have published
(Shah et al., 2016), forskolin did not appear to stimulate ATP12A
and acidify the ASL (Figures 2A, 7A,D). We confirmed our
results, by measuring the activity of ATP12A (using apical 0K+
or ouabain) in the presence or absence of forskolin. The results
showed that (i) forskolin did not induce any change in pHi
(Supplementary Figure 2) and (ii) the ouabain or 0K+-induced
changes in pHi were not significantly different whether forskolin
was present or not, indicating that ATP12A activity was not
altered by a rise in cAMP. The study by Shah et al. (2016) showed
that Fsk and IBMX induced CF ASL acidification, but did not
explicitly demonstrate the role of ATP12A in this process in
human cells. Moreover, in cultured porcine airway epithelial cells,
ouabain only partially inhibited the cAMP-induced acidification.
Although we cannot ascertain the reason behind this discrepancy,
differences in the methodology in assessing ASL pH or culture
conditions could potentially explain it.
Several groups have studied the in vivo effect of cardiac
glycosides, including ouabain, in inhaled form, on bronchial
reactivity in asthma (Agrawal et al., 1986; Knox et al.,
1988; Hulks and Patel, 1989). Indeed in the 1980s, a study
conducted in England and Wales showed a correlation between
asthma mortality and dietary salt intake (Burney, 1987) and
it was thought that inhibiting Na+/K+-ATPase would increase
the intracellular concentration of Na+, inhibiting Na+-Ca2+
FIGURE 6 | Chronic esomeprazole does not disrupt epithelial integrity of CF
hAECs. (A) Effect of increasing concentrations of apical esomeprazole on
TransEpithelial Electrical Resistance (TEER) and Fluorescein Flux measured in
Ussing chambers in the presence of a basolateral to apical Cl− gradient
(n = 5, five donors). (B,C) Effect of increasing concentrations of apical eso on
resting short-circuit current (Isc, B, n = 5), and (C) amiloride-sensitive Isc
(1Isc(amil), black triangle, n = 5), Fsk-induced Isc (1Isc(Fsk), open triangle,
n = 5), CFTRinh172-sensitive Isc (1Isc(172), open diamond, n = 5) and
UTP-induced Isc (1Isc(UTP), black circles, n = 5).
exchange, and thereby increasing contractility of smooth muscle
cells. In one study, Agrawal et al. (1986) showed that a low dose
of ouabain-induced bronchodilatation in 6 out of 10 asthmatic
subjects, whereas higher doses induced bronchoconstriction.
However, two more studies reported no effect of inhaled ouabain
on FEV1 or bronchial reactivity to histamine in asthmatic patients
(Knox et al., 1988; Hulks and Patel, 1989). Only one study
has reported the effect of topical ouabain in the airways of CF
patients (originally to study the role of the Na+/K+-ATPase
on Nasal Potential Difference (NPD) in CF nasal epithelium)
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FIGURE 7 | Chronic esomeprazole increases ASL pH in primary CF hAECs. CF hAECs were treated overnight with 50, 100, or 300 µM apical esomeprazole and
ASL pH was measured under resting condition (A–C, n ≥ 7, four to six donors, paired t-test) and after stimulation with forskolin (A,D, Fsk, basolateral, 10 µM, n ≥ 7,
four to six donors, ANOVA with Dunnett’s post-test). (A) Mean kinetic data of ASL pH of CF hAECs treated with increasing concentrations of esomeprazole.
(B) Paired data of ASL pH for each independent experiment after treatment with 50 µM (left panel), 100 µM (middle panel), or 300 µM (right panel) of Eso. (C) Dose
response of ASL pH in response to Eso. (D) Forskolin-induced changes in ASL pH in cells treated with 50, 100, 300 µM esomeprazole.
and showed no effect on NPD in people with CF and control
subjects (Peckham et al., 1995). However, this was done over
a short period of time: NPD was measured every 15 min for
an hour after application of ouabain. This time-frame would be
too short to observe any effect on pH. Taken together with our
results, these studies suggest that ouabain is not a good candidate
to target pH homeostasis as a means to improve CF airway
disease.
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FIGURE 8 | Additive effect of acute esomeprazole and K+-free solution on pHi. (A) CF hAECs were exposed acutely to apical esomeprazole (Eso, 300 µM), K+-free
solution (0K+) or both. (B) Summary data of the effect of Eso and K+ free solution on pHi (n = 11, four donors, Repeated Measures (RM)-ANOVA with Tukey
post-test).
FIGURE 9 | Chronic esomeprazole treatment targets ATP12A. (A) CF hAECs were treated for 24 h with 300 µM apical esomeprazole (Eso) and ATP12A mRNA
levels measured by RT-qPCR (n = 8, four donors, paired t-test). (B) CF hAECs were transfected with the CRISPR-Cas9 vector, PX462, containing gRNA sequences
targeting upstream and downstream of ATP12A exon 2. ATP12A knock-down was confirmed by RT-qPCR which showed a decrease of 17.1 ± 4.4% (NT:
non-transfected, Tf: Transfected; n = 6, four donors, paired t-test). (C) CF hAECs transfected or not were treated overnight with 300 µM Eso and ASL pH was
monitored the following day (n = 6, four donors, two-way ANOVA with Tukey post-test).
Because of the significant sequence homology between
different members of the proton/potassium ATPase family, and
the fact that PPIs inhibit the gastric ATPase by binding to cysteine
residues, we hypothesized that these inhibitors could also target
the non-gastric H+/K+-ATPase. To test this we investigated
the effect of the PPI esomeprazole. It belongs to the second
generation of PPIs, which are more stable than the 1st generation,
and remain bound to the gastric H+/K+-ATPase, thus inhibiting
H+ secretion until new proteins are synthesized (Andersson
et al., 2001). Importantly, our results showed that esomeprazole
increased the ASL pH in CF hAECs, and furthermore, that this
was not accompanied by any deleterious effects as observed
with ouabain treatment. Although the intracellular acidification
induced by acute esomeprazole exposure appeared to be
independent of the non-gastric H+/K+-ATPase, its chronic
effect on ASL pH was linked to a decrease in ATP12A mRNA
expression (Figure 9A) and CRISPR-Cas9 experiments suggested
that esomeprazole targeted the non-gastric H+/K+-ATPase in
order to increase ASL pH (Figure 9B,C). Interestingly, the
inhibitory effect of PPIs on ATP12A has been reported as a
potential therapeutic approach in treating the inflammatory
process in chronic rhinosinusitis (Min et al., 2017). PPIs are
mainly prescribed for GERD and the association between GERD
and lung diseases has been established although the mechanism
of action and causality have not. Accordingly, there has been
an interest in the effect of PPI on chronic lung diseases and
although results are controversial (Laheij et al., 2004; Filion et al.,
2014; Benson et al., 2015; Lee et al., 2015; Othman et al., 2016),
PPIs appear to have anti-inflammatory properties in COPD and
IPF (Ghebremariam et al., 2015; Xiong et al., 2016). One of
the hallmarks of the lung pathophysiology in CF is the chronic
inflammation. It is characterized by an excessive neutrophilic
infiltration of the airways, abundant protease (neutrophil elastase
(Le Gars et al., 2013) and bacterial elastase (Saint-Criq et al.,
2018)) and elevated levels of IL-1 and IL-8 in the CF airways
lumen (Konstan et al., 1994; Balough et al., 1995; Armstrong et al.,
1997; Montgomery et al., 2018). We can therefore hypothesize
that the use of esomeprazole in CF could also dampen the
chronic inflammation observed in CF airways. In addition
to anti-inflammatory properties, PPIs have shown antioxidant
features in various cell types, another hallmark of the CF airway
pathophysiology mainly due to the large neutrophilic infiltration.
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In vitro, the first generation PPI, omeprazole, was shown to
scavenge hypochlorous acid (Lapenna et al., 1996) and in vivo,
this PPI prevented stress-induced ulcer formation by blocking the
generation of ∗OH (Biswas et al., 2003), whereas esomeprazole
prevented the depletion of the antioxidant glutathione induced
by indomethacin in rat gastric mucosa (Pastoris et al., 2008). PPIs
have also shown antimicrobial properties. In vitro, esomeprazole
decreased Pseudomonas aeruginosa and Staphylococcus aureus
biomass and increased killing by conventional antibiotics. It also
largely inhibited biofilm formation by these two bacterial species
(Singh et al., 2012). Sasaki also reported an antiviral effect of
lansoprazole in tracheal cells by reducing their susceptibility to
rhinovirus infection (through a decrease in ICAM-1 that serves
as the receptor for rhinovirus) (Sasaki et al., 2005). Although
we have not determined the effects of chronic esomeprazole on
ASL hydration, mucus viscosity or bacterial killing in primary CF
hAECs, other groups have reported that small changes in ASL
pH (<0.2 pH) were linked to an increased bactericidal activity
and a decreased mucus viscosity in human non-CF airway cells
(Shah et al., 2016). This suggests that the changes in ASL pH
we have observed could have beneficial effects in CF airway
disease.
In CF, 80 to 90% of patients have silent or symptomatic
gastroesophageal reflux (Ledson et al., 1998; Button et al.,
2005; Blondeau et al., 2008) and therefore a large proportion
of these patients use PPIs. PPIs serve to reduce acid reflux
but also compensate for the lack of gastrointestinal secretion
(due to defective CFTR), and thereby enhance the benefit of
pancreatic enzyme replacement therapy. Indeed, several studies
have shown the beneficial effect of PPI use in children with
CF when looking at steatorrhea and nutritional status (Tran
et al., 1998; Proesmans and De Boeck, 2003), and it is well
acknowledged that in these cases, PPIs such as omeprazole and
lansoprazole, show improvement in fat absorption. However,
the effect of PPI on pulmonary function is more controversial.
PPIs decrease acid content of gastric juice and Palm et al.
(2012) showed that there was a negative correlation between
non-acid reflux burden and FEV1. Another study, looking at
children with CF between 2009 and 2014, reported that PPI use
was associated with a decline in percent predicted (pp)FEV1
as well as an increase in future pulmonary exacerbation rate
(van Horck et al., 2018). This was also reported in adults with
CF in which PPI use was associated with an increase in the
number of hospitalizations due to pulmonary exacerbations
(Ayoub et al., 2017). However, by differentiating those on gastric
acid inhibitors because of GERD, from those taking PPIs because
of fat malabsorption, van der Doef et al. (2009) showed that only
the children with CF taking gastric acid inhibitors because of
GERD presented a reduced pulmonary function. This challenges
the role of PPIs in pulmonary exacerbations in CF and suggests
that GERD rather than PPI use is involved in pulmonary
decline.
Since our current study showed a beneficial effect of
esomeprazole on CF airway ASL pH homeostasis, and
considering the other potential benefits of PPIs against
bacterial and viral infections, oxidative stress and inflammatory
processes, we propose that inhaled use of PPIs in CF
airways might alleviate CF lung pathophysiology. Interestingly,
novel H+/K+-ATPase inhibitors, termed P-CABs (Potassium-
Competitive Acid Blockers), such as Vonoprazan, are more
potent than PPIs for eradication of clarithromycin-resistant
Helicobacter pylori (Li et al., 2018). Thus it will be interesting
to test the effects of these new H+ pump inhibitors
on inflammation, infection, and pH homeostasis in CF
airways.
ETHICS STATEMENT
The cells were obtained under protocol #03-1396 approved by
the University of North Carolina at Chapel Hill Biomedical
Institutional Review Board.
AUTHOR CONTRIBUTIONS
LD, JT, AY, and SR performed experiments and analyzed data.
MG designed and performed experiments, provided reagents,
analyzed data and edited the manuscript. VS-C designed
and performed experiments, analyzed data and wrote the
manuscript.
FUNDING
This work was supported by two CF Trust Strategic Research
Centre grants (SRC003 and SRC013) and a Medical Research
Council (MRC) Confidence in Concept grant (MC_PC_15030).
SR was supported by Versus Arthritis (grant 20771), and by
the MRC and Arthritis Research UK as part of the Centre for
Integrated Research into Musculoskeletal Ageing (CIMA, grant
references JXR 10641, MR/P020941/1 and MR/R502182/1). Cells
from Dr. Randell were supported by Cystic Fibrosis Foundation
grant (BOUCHE15R0) and NIH grant (P30DK065988).
ACKNOWLEDGMENTS
We wish to thank Dr. Robert Tarran for the advices on setting
up the ASL pH measurements. We would like to acknowledge
Drs. Scott H. Randell and Leslie Fulcher (Marsico Lung Institute,
The University of North Carolina at Chapel Hill, United States)
for providing CF primary airway epithelial cells from the CFFT
collection and CF and non-CF primary airway epithelial cells
from the UNC CF Center Tissue Procurement and Cell Culture
Core.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphar.
2018.01462/full#supplementary-material
Frontiers in Pharmacology | www.frontiersin.org 13 December 2018 | Volume 9 | Article 1462
fphar-09-01462 December 8, 2018 Time: 10:14 # 14
Delpiano et al. Esomeprazole Regulates CF ASL pH
REFERENCES
Agrawal, K. P., Reed, C. E., Hyatt, R. E., Imber, W. E., and Krell, W. S. (1986).
Airway responses to inhaled ouabain in subjects with and without asthma.Mayo
Clin. Proc. 61, 778–784. doi: 10.1016/S0025-6196(12)64816-2
Andersson, T., Hassan-Alin, M., Hasselgren, G., Rohss, K., and Weidolf, L. (2001).
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
Clin. Pharmacokinet. 40, 411–426. doi: 10.2165/00003088-200140060-00003
Armstrong, D. S., Grimwood, K., Carlin, J. B., Carzino, R., Gutierrez, J. P., Hull, J.,
et al. (1997). Lower airway inflammation in infants and young children with
cystic fibrosis. Am. J. Respir. Crit. Care Med. 156, 1197–1204. doi: 10.1164/
ajrccm.156.4.96-11058
Ayoub, F., Lascano, J., and Morelli, G. (2017). Proton pump inhibitor use is
associated with an increased frequency of hospitalization in patients with cystic
fibrosis. Gastroenterol. Res. 10, 288–293. doi: 10.14740/gr917w
Balough, K., Mccubbin, M., Weinberger, M., Smits, W., Ahrens, R., and Fick, R.
(1995). The relationship between infection and inflammation in the early stages
of lung disease from cystic fibrosis. Pediatr. Pulmonol. 20, 63–70. doi: 10.1002/
ppul.1950200203
Benson, V. S., Mullerova, H., Vestbo, J., Wedzicha, J. A., Patel, A., and Hurst,
J. R. (2015). Associations between gastro-oesophageal reflux, its management
and exacerbations of chronic obstructive pulmonary disease. Respir. Med. 109,
1147–1154. doi: 10.1016/j.rmed.2015.06.009
Berkebile, A. R., and McCray, P. B. Jr. (2014). Effects of airway surface liquid
pH on host defense in cystic fibrosis. Int. J. Biochem. Cell Biol. 52, 124–129.
doi: 10.1016/j.biocel.2014.02.009
Birket, S. E., Davis, J. M., Fernandez, C. M., Tuggle, K. L., Oden, A. M., Chu, K. K.,
et al. (2018). Development of an airway mucus defect in the cystic fibrosis rat.
JCI Insight 3:97199. doi: 10.1172/jci.insight.97199
Biswas, K., Bandyopadhyay, U., Chattopadhyay, I., Varadaraj, A., Ali, E., and
Banerjee, R. K. (2003). A novel antioxidant and antiapoptotic role of
omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Biol.
Chem. 278, 10993–11001. doi: 10.1074/jbc.M210328200
Blondeau, K., Dupont, L. J., Mertens, V., Verleden, G., Malfroot, A., Vandenplas, Y.,
et al. (2008). Gastro-oesophageal reflux and aspiration of gastric contents in
adult patients with cystic fibrosis. Gut 57, 1049–1055. doi: 10.1136/gut.2007.
146134
Boyle, M. P., Bell, S. C., Konstan, M. W., Mccolley, S. A., Rowe, S. M., Rietschel, E.,
et al. (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor)
for treatment of patients with cystic fibrosis who have a phe508del CFTR
mutation: a phase 2 randomised controlled trial. Lancet Respir. Med. 2, 527–538.
doi: 10.1016/S2213-2600(14)70132-8
Burney, P. (1987). A diet rich in sodium may potentiate asthma. Epidemiologic
evidence for a new hypothesis. Chest 91, 143S–148S. doi: 10.1378/chest.91.6_
Supplement.143S
Button, B. M., Roberts, S., Kotsimbos, T. C., Levvey, B. J., Williams, T. J.,
Bailey, M., et al. (2005). Gastroesophageal reflux (symptomatic and silent): a
potentially significant problem in patients with cystic fibrosis before and after
lung transplantation. J. Heart Lung Transplant. 24, 1522–1529. doi: 10.1016/j.
healun.2004.11.312
Coakley, R. D., Grubb, B. R., Paradiso, A. M., Gatzy, J. T., Johnson, L. G., Kreda,
S. M., et al. (2003). Abnormal surface liquid pH regulation by cultured cystic
fibrosis bronchial epithelium. Proc. Natl. Acad. Sci. U.S.A. 100, 16083–16088.
doi: 10.1073/pnas.2634339100
Crambert, G., Horisberger, J. D., Modyanov, N. N., and Geering, K. (2002). Human
nongastric H+-K+-ATPase: transport properties of ATP1al1 assembled with
different beta-subunits. Am. J. Physiol. Cell Physiol. 283, C305–C314. doi: 10.
1152/ajpcell.00590.2001
De Boeck, K., and Amaral, M. D. (2016). Classification of CFTR mutation classes -
Authors’ reply. Lancet Respir. Med. 4:e39. doi: 10.1016/S2213-2600(16)30189-8
Filion, K. B., Chateau, D., Targownik, L. E., Gershon, A., Durand, M., Tamim, H.,
et al. (2014). Proton pump inhibitors and the risk of hospitalisation for
community-acquired pneumonia: replicated cohort studies with meta-analysis.
Gut 63, 552–558. doi: 10.1136/gutjnl-2013-304738
Garland, A. L., Walton, W. G., Coakley, R. D., Tan, C. D., Gilmore, R. C., Hobbs,
C. A., et al. (2013). Molecular basis for pH-dependent mucosal dehydration
in cystic fibrosis airways. Proc. Natl. Acad. Sci. U.S.A. 110, 15973–15978. doi:
10.1073/pnas.1311999110
Ghebremariam, Y. T., Cooke, J. P., Gerhart, W., Griego, C., Brower, J. B., Doyle-
Eisele, M., et al. (2015). Pleiotropic effect of the proton pump inhibitor
esomeprazole leading to suppression of lung inflammation and fibrosis.
J. Transl. Med. 13:249. doi: 10.1186/s12967-015-0614-x
Hulks, G., and Patel, K. R. (1989). The effect of inhaled ouabain on bronchomotor
tone and histamine responsiveness in asthmatic patients. Pulm. Pharmacol. 2,
161–162. doi: 10.1016/0952-0600(89)90041-0
Iwakiri, K., Kinoshita, Y., Habu, Y., Oshima, T., Manabe, N., Fujiwara, Y., et al.
(2016). Evidence-based clinical practice guidelines for gastroesophageal reflux
disease 2015. J. Gastroenterol. 51, 751–767. doi: 10.1007/s00535-016-1227-8
Kelly, J. (2017). Environmental scan of cystic fibrosis research worldwide. J. Cyst.
Fibros. 16, 367–370. doi: 10.1016/j.jcf.2016.11.002
Knox, A. J., Tattersfield, A. E., and Britton, J. R. (1988). The effect of inhaled
ouabain on bronchial reactivity to histamine in man. Br. J. Clin. Pharmacol.
25, 758–760. doi: 10.1111/j.1365-2125.1988.tb05264.x
Konstan, M. W., Hilliard, K. A., Norvell, T. M., and Berger, M. (1994).
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically
mild lung disease suggest ongoing infection and inflammation. Am. J. Respir.
Crit. Care Med. 150, 448–454. doi: 10.1164/ajrccm.150.2.8049828
Laheij, R. J., Sturkenboom, M. C., Hassing, R. J., Dieleman, J., Stricker, B. H.,
and Jansen, J. B. (2004). Risk of community-acquired pneumonia and use of
gastric acid-suppressive drugs. JAMA 292, 1955–1960. doi: 10.1001/jama.292.
16.1955
Lapenna, D., De Gioia, S., Ciofani, G., Festi, D., and Cuccurullo, F. (1996).
Antioxidant properties of omeprazole. FEBS Lett. 382, 189–192. doi: 10.1016/
0014-5793(96)00155-X
Larre, I., Lazaro, A., Contreras, R. G., Balda, M. S., Matter, K., Flores-
Maldonado, C., et al. (2010). Ouabain modulates epithelial cell tight junction.
Proc. Natl. Acad. Sci. U.S.A. 107, 11387–11392. doi: 10.1073/pnas.1000500107
Le Gars, M., Descamps, D., Roussel, D., Saussereau, E., Guillot, L., Ruffin, M.,
et al. (2013). Neutrophil elastase degrades cystic fibrosis transmembrane
conductance regulator via calpains and disables channel function in vitro and
in vivo. Am. J. Respir. Crit. Care Med. 187, 170–179. doi: 10.1164/rccm.201205-
0875OC
Ledson, M. J., Tran, J., and Walshaw, M. J. (1998). Prevalence and mechanisms of
gastro-oesophageal reflux in adult cystic fibrosis patients. J. R. Soc. Med. 91, 7–9.
doi: 10.1177/014107689809100103
Lee, S. W., Lin, C. H., Lien, H. C., Lee, T. Y., Yeh, H. Z., and Chang, C. S.
(2015). Proton pump inhibitors did not increase risk of pneumonia in patients
with chronic obstructive pulmonary disease. J. Clin. Med. Res. 7, 880–883.
doi: 10.14740/jocmr2322w
Lennox, A. T., Coburn, S. L., Leech, J. A., Heidrich, E. M., Kleyman, T. R., Wenzel,
S. E., et al. (2018). ATP12A promotes mucus dysfunction during Type 2 airway
inflammation. Sci. Rep. 8:2109. doi: 10.1038/s41598-018-20444-8
Li, M., Oshima, T., Horikawa, T., Tozawa, K., Tomita, T., Fukui, H., et al. (2018).
Systematic review with meta-analysis: vonoprazan, a potent acid blocker,
is superior to proton-pump inhibitors for eradication of clarithromycin-
resistant strains of Helicobacter pylori. Helicobacter 23:e12495. doi: 10.1111/hel.
12495
Luan, X., Belev, G., Tam, J. S., Jagadeeshan, S., Hassan, N., Gioino, P., et al.
(2017). Cystic fibrosis swine fail to secrete airway surface liquid in response
to inhalation of pathogens. Nat. Commun. 8:786. doi: 10.1038/s41467-017-
00835-7
Min, J. Y., Ocampo, C. J., Stevens, W. W., Price, C. P. E., Thompson, C. F.,
Homma, T., et al. (2017). Proton pump inhibitors decrease eotaxin-3/CCL26
expression in patients with chronic rhinosinusitis with nasal polyps: possible
role of the nongastric H,K-ATPase. J. Allergy Clin. Immunol. 139, 130.e11–
141.e11. doi: 10.1016/j.jaci.2016.07.020
Montgomery, S. T., Dittrich, A. S., Garratt, L. W., Turkovic, L., Frey, D. L., Stick,
S. M., et al. (2018). Interleukin-1 is associated with inflammation and structural
lung disease in young children with cystic fibrosis. J. Cyst. Fibros. 17, 715–722.
doi: 10.1016/j.jcf.2018.05.006
Namkung, W., Song, Y., Mills, A. D., Padmawar, P., Finkbeiner, W. E., and
Verkman, A. S. (2009). In situ measurement of airway surface liquid [K+]
Frontiers in Pharmacology | www.frontiersin.org 14 December 2018 | Volume 9 | Article 1462
fphar-09-01462 December 8, 2018 Time: 10:14 # 15
Delpiano et al. Esomeprazole Regulates CF ASL pH
using a ratioable K+-sensitive fluorescent dye. J. Biol. Chem. 284, 15916–15926.
doi: 10.1074/jbc.M808021200
Othman, F., Crooks, C. J., and Card, T. R. (2016). Community acquired pneumonia
incidence before and after proton pump inhibitor prescription: population
based study. BMJ 355:i5813. doi: 10.1136/bmj.i5813
Palm, K., Sawicki, G., and Rosen, R. (2012). The impact of reflux burden on
Pseudomonas positivity in children with cystic fibrosis. Pediatr. Pulmonol. 47,
582–587. doi: 10.1002/ppul.21598
Pastoris, O., Verri, M., Boschi, F., Kastsiuchenka, O., Balestra, B., Pace, F.,
et al. (2008). Effects of esomeprazole on glutathione levels and mitochondrial
oxidative phosphorylation in the gastric mucosa of rats treated with
indomethacin. Naunyn Schmiedebergs Arch. Pharmacol. 378, 421–429. doi: 10.
1007/s00210-008-0314-7
Peckham, D. G., Conn, A., Chotai, C., Lewis, S., and Knox, A. J. (1995). Effect of
oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential
difference in patients with cystic fibrosis. Clin. Sci. 89, 277–284. doi: 10.1042/
cs0890277
Pezzulo, A. A., Tang, X. X., Hoegger, M. J., Alaiwa, M. H., Ramachandran, S.,
Moninger, T. O., et al. (2012). Reduced airway surface pH impairs bacterial
killing in the porcine cystic fibrosis lung. Nature 487, 109–113. doi: 10.1038/
nature11130
Proesmans, M., and De Boeck, K. (2003). Omeprazole, a proton pump inhibitor,
improves residual steatorrhoea in cystic fibrosis patients treated with high dose
pancreatic enzymes. Eur. J. Pediatr. 162, 760–763. doi: 10.1007/s00431-003-
1309-5
Quinton, P. M. (2008). Cystic fibrosis: impaired bicarbonate secretion and
mucoviscidosis. Lancet 372, 415–417. doi: 10.1016/S0140-6736(08)61162-9
Ramachandran, S., Krishnamurthy, S., Jacobi, A. M., Wohlford-Lenane, C., Behlke,
M. A., Davidson, B. L., et al. (2013). Efficient delivery of RNA interference
oligonucleotides to polarized airway epithelia in vitro. Am. J. Physiol. Lung Cell.
Mol. Physiol. 305, L23–L32. doi: 10.1152/ajplung.00426.2012
Randell, S. H., Fulcher, M. L., O’neal, W., and Olsen, J. C. (2011). Primary epithelial
cell models for cystic fibrosis research. Methods Mol. Biol. 742, 285–310. doi:
10.1007/978-1-61779-120-8_18
Rincon-Heredia, R., Flores-Benitez, D., Flores-Maldonado, C., Bonilla-Delgado, J.,
Garcia-Hernandez, V., Verdejo-Torres, O., et al. (2014). Ouabain induces
endocytosis and degradation of tight junction proteins through ERK1/2-
dependent pathways. Exp. Cell Res. 320, 108–118. doi: 10.1016/j.yexcr.2013.
10.008
Rowe, S. M., Mccolley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W.,
et al. (2017). Lumacaftor/Ivacaftor treatment of patients with cystic fibrosis
heterozygous for F508del-CFTR. Ann. Am. Thorac. Soc. 14, 213–219. doi: 10.
1513/AnnalsATS.201609-689OC
Saint-Criq, V., and Gray, M. A. (2017). Role of CFTR in epithelial physiology. Cell.
Mol. Life Sci. 74, 93–115. doi: 10.1007/s00018-016-2391-y
Saint-Criq, V., Kim, S. H., Katzenellenbogen, J. A., and Harvey, B. J. (2013).
Non-genomic estrogen regulation of ion transport and airway surface liquid
dynamics in cystic fibrosis bronchial epithelium. PLoS One 8:e78593. doi: 10.
1371/journal.pone.0078593
Saint-Criq, V., Villeret, B., Bastaert, F., Kheir, S., Hatton, A., Cazes, A., et al. (2018).
Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and
humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-
IL-6-antimicrobial-repair pathway. Thorax 73, 49–61. doi: 10.1136/thoraxjnl-
2017-210298
Sasaki, T., Yamaya, M., Yasuda, H., Inoue, D., Yamada, M., Kubo, H., et al.
(2005). The proton pump inhibitor lansoprazole inhibits rhinovirus infection
in cultured human tracheal epithelial cells. Eur. J. Pharmacol. 509, 201–210.
doi: 10.1016/j.ejphar.2004.12.042
Schultz, A., Puvvadi, R., Borisov, S. M., Shaw, N. C., Klimant, I., Berry, L. J., et al.
(2017). Airway surface liquid pH is not acidic in children with cystic fibrosis.
Nat. Commun. 8:1409. doi: 10.1038/s41467-017-00532-5
Shah, V. S., Meyerholz, D. K., Tang, X. X., Reznikov, L., Abou Alaiwa, M., Ernst,
S. E., et al. (2016). Airway acidification initiates host defense abnormalities in
cystic fibrosis mice. Science 351, 503–507. doi: 10.1126/science.aad5589
Singh, V., Arora, V., Alam, M. J., and Garey, K. W. (2012). Inhibition of biofilm
formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus
aureus. Antimicrob. Agents Chemother. 56, 4360–4364. doi: 10.1128/AAC.
00544-12
Song, Y., Salinas, D., Nielson, D. W., and Verkman, A. S. (2006). Hyperacidity of
secreted fluid from submucosal glands in early cystic fibrosis. Am. J. Physiol.
Cell Physiol. 290, C741–C749. doi: 10.1152/ajpcell.00379.2005
Suprynowicz, F. A., Upadhyay, G., Krawczyk, E., Kramer, S. C., Hebert, J. D.,
Liu, X., et al. (2012). Conditionally reprogrammed cells represent a stem-like
state of adult epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 109, 20035–20040.
doi: 10.1073/pnas.1213241109
Tan, C. D., Hobbs, C., Sameni, M., Sloane, B. F., Stutts, M. J., and Tarran, R.
(2014). Cathepsin B contributes to Na+ hyperabsorption in cystic fibrosis
airway epithelial cultures. J. Physiol. 592, 5251–5268. doi: 10.1113/jphysiol.2013.
267286
Tang, X. X., Ostedgaard, L. S., Hoegger, M. J., Moninger, T. O., Karp, P. H.,
Mcmenimen, J. D., et al. (2016). Acidic pH increases airway surface liquid
viscosity in cystic fibrosis. J. Clin. Invest. 126, 879–891. doi: 10.1172/JCI83922
Taylor-Cousar, J. L., Munck, A., Mckone, E. F., Van Der Ent, C. K., Moeller, A.,
Simard, C., et al. (2017). Tezacaftor-ivacaftor in patients with cystic fibrosis
homozygous for Phe508del. N. Engl. J. Med. 377, 2013–2023. doi: 10.1056/
NEJMoa1709846
Tran, T. M., Van Den Neucker, A., Hendriks, J. J., Forget, P., and Forget, P. P.
(1998). Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatr. 87,
553–558. doi: 10.1111/j.1651-2227.1998.tb01503.x
Turner, M. J., Saint-Criq, V., Patel, W., Ibrahim, S. H., Verdon, B., Ward, C.,
et al. (2016). Hypercapnia modulates cAMP signalling and cystic fibrosis
transmembrane conductance regulator-dependent anion and fluid
secretion in airway epithelia. J. Physiol. 594, 1643–1661. doi: 10.1113/
JP271309
van der Doef, H. P., Arets, H. G., Froeling, S. P., Westers, P., and Houwen,
R. H. (2009). Gastric acid inhibition for fat malabsorption or gastroesophageal
reflux disease in cystic fibrosis: longitudinal effect on bacterial colonization
and pulmonary function. J. Pediatr. 155, 629–633. doi: 10.1016/j.jpeds.2009.
06.040
Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Cao, D., Neuberger, T.,
et al. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR
potentiator, VX-770. Proc. Natl. Acad. Sci. U.S.A. 106, 18825–18830. doi: 10.
1073/pnas.0904709106
van Horck, M., Van De Kant, K., Winkens, B., Wesseling, G., Gulmans, V.,
Hendriks, H., et al. (2018). Risk factors for lung disease progression in children
with cystic fibrosis. Eur. Respir. J. 51:1702509. doi: 10.1183/13993003.02509-
2017
Vertex (2017). Available at: http://investors.vrtx.com/releasedetail.cfm?releaseid=
1019156
Xiong, W., Zhang, Q. S., Zhao, W., Ding, W., Liu, J. M., and Zhao, Y. F. (2016).
A 12-month follow-up study on the preventive effect of oral lansoprazole on
acute exacerbation of chronic obstructive pulmonary disease. Int. J. Exp. Pathol.
97, 107–113. doi: 10.1111/iep.12173
Zhang, D., Ciciriello, F., Anjos, S. M., Carissimo, A., Liao, J., Carlile, G. W., et al.
(2012). Ouabain mimics low temperature rescue of F508del-CFTR in cystic
fibrosis epithelial cells. Front. Pharmacol. 3:176. doi: 10.3389/fphar.2012.00176
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Delpiano, Thomas, Yates, Rice, Gray and Saint-Criq. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 15 December 2018 | Volume 9 | Article 1462
